Physician profile
John B Williamson
NPI 1922069186
$6,068.03
in general payments reported to CMS, 2019-2025
25 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $1,843 · 2021: $692 · 2022: $2,045 · 2023: $374 · 2024: $416 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,091.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nutech Spine, INC. | $1,500.00 | 2020 | |
| Abbott Laboratories | $1,128.66 | 2019-2025 | Proclaim, Eterna, Octrode |
| Relievant Medsystems, INC. | $840.39 | 2022 | |
| Spinal Simplicity, LLC | $536.20 | 2022 | |
| Boston Scientific Corporation | $425.87 | 2021-2022 | |
| Vertos Medical, INC. | $332.39 | 2021-2024 | Mild Device Kit |
| Abbvie INC. | $265.32 | 2021-2025 | Qulipta, Ubrelvy |
| Si-Bone, INC. | $226.81 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $140.91 | 2021-2024 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.79 | 2022-2024 | Xifaxan, Relistor |
| Vertiflex, INC. | $103.55 | 2019 | |
| Gilead Sciences, INC. | $74.77 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $45.74 | 2020-2021 | |
| Spr Therapeutics, INC | $44.61 | 2025 | Sprint Pns System |
| Mdd US Operations, LLC | $42.31 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $36.38 | 2021 | |
| Pacira Therapeutics, INC. | $32.97 | 2019-2021 | |
| Depuy Synthes Sales INC. | $29.06 | 2021-2025 | Monovisc, Orthovisc |
| Nevro Corp. | $21.45 | 2024 | Senza |
| Nalu Medical, INC. | $20.98 | 2025 | Nalu Neurostimulation System |
| Bioventus LLC | $18.81 | 2023 | Durolane |
| Novo Nordisk INC | $18.18 | 2023 | Wegovy |
| Merck Sharp & Dohme LLC | $16.82 | 2025 | Bridion |
| Pfizer INC. | $13.96 | 2020 | |
| Hydrocision, INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.